Crizotinib, a class Ia small molecule dual inhibitor of c-MET and anaplastic lymphoma kinase (ALK) had been proposed for advanced non-small cell lung cancer therapy with activation of either c-ros oncogene 1 (ROS-1) or ALK [110]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.